TETON trials: Inhaled treprostinil lessens FVC decline in IPF at 52 weeks

ORLANDO — Two replicate phase 3 trials have shown that adults with idiopathic pulmonary fibrosis had less FVC decline with 52-week inhaled treprostinil vs. placebo, according to a pair of presentations here.In addition to being presented at the American Thoracic Society International Conference, these findings were simultaneously published in The New England Journal of Medicine.

Raccontata dahealio.com